EP0469065B1 - Proteine recombinante de fusion anticorps-toxine - Google Patents

Proteine recombinante de fusion anticorps-toxine Download PDF

Info

Publication number
EP0469065B1
EP0469065B1 EP90907767A EP90907767A EP0469065B1 EP 0469065 B1 EP0469065 B1 EP 0469065B1 EP 90907767 A EP90907767 A EP 90907767A EP 90907767 A EP90907767 A EP 90907767A EP 0469065 B1 EP0469065 B1 EP 0469065B1
Authority
EP
European Patent Office
Prior art keywords
fusion protein
antibody
tac
construct
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP90907767A
Other languages
German (de)
English (en)
Other versions
EP0469065A4 (en
EP0469065A1 (fr
Inventor
Ira H. Pastan
David Fitzgerald
Cary L. Queen
Thomas A. Waldmann
Vijay Kumar Chaudhary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
US Department of Health and Human Services
Protein Design Labs Inc
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Protein Design Labs Inc, US Department of Commerce filed Critical US Department of Health and Human Services
Publication of EP0469065A1 publication Critical patent/EP0469065A1/fr
Publication of EP0469065A4 publication Critical patent/EP0469065A4/en
Application granted granted Critical
Publication of EP0469065B1 publication Critical patent/EP0469065B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Definitions

  • the present application relates to the production of improved toxins utilizing PE, and more particulary, to the synthesis of recombinant antibody-toxin fusion proteins which are capable of effectively and selectively killing cells bearing appropriate antigens or receptors.
  • the work described herein was partially supported by the U.S. Government.
  • FIG. 1(a) illustrates a schematic construction of expression plasmid pVC70108.
  • Plasmid pVC70108 contains a fusion gene encoding various domains of anti-Tac: V H - variable domain of the heavy chain (first 116 amino acids of mature heavy chain), 15 amino acid linker [(gly-gly-gly-gly-Ser)3], V L -variable domain of the light chain (first 106 amino acids of mature light chain) and amino acids 253-613 of PE, which possesses translocating and ADP ribosylating activity, as a single polypeptide chain.
  • the encoded protein is called an antibody-toxin fusion protein or more specifically anti-Tac(Fv)-PE40.
  • the fusion gene is under control of a T7 promoter linked to Shine-Delgarno region and initiation codon (PT7).
  • E . coli strain BL21 ( ⁇ DE3) carrying pVC70108 was used to express hybrid protein upon IPTG induction.
  • Amp r ⁇ lactamase gene; B, BamHI, A, AvaI.
  • Oligonucleotides used for PCR have been shown as horizontal arrows.
  • plasmid pVC701 four extra bases have been shown in a hatched box.
  • Figure 1(b) shows the oligonucleotides used for polymerase chain reaction (PCR) with VK074, VK075 and VK076 each shown on two lines. Portions of VK073 and VK075 are complimentary to the noncoding strands of heavy and light chain cDNA, while that of VK074 and VK076 are complimentary to the coding strands of heavy and light chains cDNAs, respectively. VK073 and VK074 were used for amplifying V H segment using anti-Tac heavy chain cDNA while VK075 and VK076 were used to generate V L segment using anti-Tac light chain cDNA as shown in Figure la. All the oligonucleotides have been written in 5' to 3' direction. Sequences complimentary to coding or noncoding strands of V L or V H cDNAs are shown in plain boxes. Sequences encoding peptide linker between V H and V L are underlined with a broken line.
  • Figure 2(a) shows the results of purification of renatured soluble anti-Tac(Fv)-PE40 by Mono Q column chromatography. Renatured material was applied on a Mono Q column; proteins were eluted with a NaCl gradient (0-0.5M) and 4 ml fractions were collected. The position of active monomeric anti-Tac(Fv)-PE40 is shown by a vertical arrow.
  • Figure 2(b) shows the results of SDS-PAGE of samples at various stages of purification.
  • the gel was stained with Coomassie blue.
  • Lane 1 total cell pellet; lane 2, spheroplasts; lane 3, 100,000 xg pellet of sonicated spheroplasts; lane 4, pool of fractions (32-33) from the Mono Q column; lane 5, pool of peak fractions from the TSK-250 column; lane 6, native PE, Mr 66 kDa.
  • Molecular weight markers are on the side with Mr in kDa.
  • Figure 3 shows the results of a cytotoxicity study of anti-Tac(Fv)-PE40 on HUT-102 cells expressing IL2 receptors. Cytotoxicity of anti-Tac(Fv)-PE40 on HUT-102 cells was determined by measuring protein synthesis with ( ⁇ ) anti-Tac(fv)-PE40; ( ⁇ ) anti-Tia(Fv)-PE40 + 10 ⁇ g anti-Tac; ( ⁇ ) anti-Tac(Fv)-PE40 + 10 ⁇ g OVB3.
  • Figure 4 shows a competition binding analysis of anti-Tac(Fv)-PE40.
  • Competition data of anti-Tac(Fv)-PE40 (open squares) and native mouse anti-Tac antibody (solid circles) with I-125 labeled tracer anti-Tac antibody to bind to Tac antigen on HUT-102 cells is shown.
  • Solid lines are computer generated idealized curves that model binding competition.
  • Ro is the bound/free ratio for tracer in the absence of competitor, and Ro/2 is the 50% inhibition point for tracer binding, from which a binding affinity of 3.5 x 109 M ⁇ 1 for anti-Tac(Fv)-PE40 is calculated, compared with 9.7 x 109 M ⁇ 1 for native anti-Tac.
  • a recombinant immunotoxin in accordance with the present invention comprises an antibody-PE40 recombinant fusion protein.
  • the fusion protein is anti-Tac(Fv)-PE40
  • the recombinant fusion protein is produced by an expression vector or plasmid comprising DNA segments which direct the synthesis of said fusion protein.
  • a composition according to the invention comprises an effective amount of the antibody-PE40 recombinant fusion protein of the invention to kill cells bearing a receptor or an antigen to which the antibody binds, and a pharmaceutically acceptable carrier.
  • a method for achieving targeted cytotoxicity comprises contacting cells targeted to be killed with a cytotoxic amount of the composition of antibody-PE40 recombinant fusion protein, said targeted cells being those having receptors or antigens to which said antibody binds, but the composition being without significant cytotoxicity to cells which lack receptors or antigens for the binding of said antibody (Table 2).
  • antibody as used herein means a portion of an immunoglobulin molecule (see W.E. Paul, ed., “Fundamental Immunology,” Raven Press, N.Y., 1984, pp. 131-165) capable of binding to an antigen.
  • the term “antibody” includes various forms of modified or altered antibodies, such as an intact immunoglobulin, an Fv fragment containing only the light and heavy chain variable regions, an Fab or (Fab)'2 fragment containing the variable regions and parts of the constant regions, a single-chain antibody (Bird et al., 1988, Science 242, 424-426; Huston et al., 1988, Proc. Nat. Acad. Sci.
  • the antibody may be of animal (especially mouse or rat) or human origin or may be chimeric (Morrison et al., 1984, Proc. Nat. Acad. Sci. USA 81, 6851-6855) or humanized (Jones et al., 1986, Nature 321, 522-525, and published UK patent application # 8707252).
  • Methods of producing antibodies suitable for use in the present invention are well known to those skilled in the art and can be found described in such publication as Harlow & Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988.
  • the genes encoding the antibody chains may be cloned in cDNA or in genomic form by any cloning procedure known to those skilled in the art.
  • fusion protein of the present invention does not affect the function of the untargeted cells to any appreciable degree or to any abnormal level.
  • the recombinant antibody-PE40 fusion protein may be composed of one or two polypeptide chains.
  • the production of a single chain fusion protein has been illustrated herein.
  • no amino acid linker would be inserted between the V H and V L sequences.
  • a termination codon would be inserted after the V H sequence, and an initiation codon and ribosome binding sequence would be inserted before the V L sequence.
  • the V L and V H sequences will be followed respectively by part or all of the light and heavy chain constant regions, e.g., the whole kappa light chain constant region and the C H 1 domain of the heavy chain constant region, with or without the heavy chain hinge domain.
  • V L , V H and PE40 genes may occur in any order on the plasmid, hence the PE40 gene may be attached to either the 5' or 3' end of either the light or heavy chain gene.
  • the PE40 gene may be attached to either the 5' or 3' end of either the light or heavy chain gene.
  • additional modifications, deletions, insertions and the like may be made to the antibody and PE40 genes.
  • deletions or changes may be made in PE40 or in the linker connecting the antibody gene to PE40, in order to increase cytotoxicity of the fusion protein toward target cells or to decrease nonspecific cytotoxicity toward cells without antigen for the antibody.
  • the V L , V H , and PE40 genes are contained on a single plasmid. Moreover, the recombinant antibody-PE40 protein after synthesis remains internal to the E. coli host cell until purified.
  • the V L gene and any light chain constant region will be on one plasmid; while the V H gene, any heavy chain constant region, and the PE40 gene will be on a second plasmid.
  • V L and/or V H genes may be preceded by a signal sequence that directs the secretion of the recombinant fusion protein from the cell (Better et al., 1988, Science 240, 1041-1043; Skerra & Pluckthun, 1988, Science 240, 1038-1041).
  • the fusion proteins of the invention may be expressed in a variety of host cells, including E. coli , other bacterial hosts, yeast, and various higher eucaryotic cells such as the COS, CHO and HeLa cells lines and myeloma cell lines.
  • the recombinant protein gene will be operably linked to appropriate expression control sequences for each host.
  • this includes a promoter such as the T7, trp, or lambda promoters, a ribosome binding site and perferably a transcription termination signal.
  • control sequences will include a promoter and preferably an enhancer derived from immunoglobulin genes, SV40, cytomegalovirus, etc., and a polyadenylation sequence, and may include splice donor and acceptor sequences.
  • the plasmids of the invention can be transferred into the chosen host cell by well-known methods such as calcium chloride transformation for E. coli and calcium phosphate treatment or electroporation for mammalian cells. Cells transformed by the plasmids can be selected by resistance to antibiotics conferred by genes contained on the plasmids, such as the amp, gpt, neo and hyg genes.
  • the recombinant fusion proteins can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see, generally, R. Scopes, "Protein Purification", Springer-Verlag, N.Y. (1982)). Substantially pure compositions of at least about 90 to 95% homogeneity are perferred, and 98 to 99% or more homogeneity most perferred, for pharmaceutical uses. Once purified, partially or to homogeneity as desired, the polypeptides may then be used therapeutically (including extracorporeally) or otherwise, such as in developing and performing assay procedures. (See, generally, Immunological Methods , Vols. I and II, Lefkovits and Pernis, eds., Academic Press, New York, N.Y. (1979 and 1981)).
  • compositions for parenteral administration are particularly useful for parenteral administration, i.e. , subcutaneously, intramuscularly or intravenously.
  • the compositions for parenteral administration will commonly comprise a solution of the antibody or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous carrier.
  • an acceptable carrier preferably an aqueous carrier.
  • aqueous carriers can be used, e.g. , water, buffered water, 0.4% saline, 0/3% glycine and the like. These solutions are sterile and generally free of undesirable matter.
  • These compositions may be sterilized by conventional, well known sterilization techniques.
  • compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
  • concentration of fusion protein in these formulations can vary widely i.e. , from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected.
  • a typical pharmaceutical composition for intramuscular injection may comprise 1 ml sterile buffered water, and 10 mg of fusion protein.
  • a typical composition for intravenous infusion may comprise 250 ml of steril Ringer's solution, and 10 mg of protein.
  • Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's Pharmaceutical Science , 15th ed., Mack Publishing Company, Easton, Pennsylvania (1980), which is incorporated herein by reference.
  • compositions containing the present fusion proteins or a cocktail thereof can be administered for prophylactic and/or therapeutic treatments.
  • compositions are administered to a patient suffering from a disease, in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose.” Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health.
  • compositions containing the present antibodies or a cocktail thereof are administered to a patient not already in a disease state to prevent the onset of disease.
  • Such an amount is defined to be a "phrophylactically effective dose.”
  • the precise amounts again depend upon the patient's state of health and general level of immunity.
  • compositions may be administered depending on the dosage and frequency as required and tolerated by the patient.
  • the composition should provide a sufficient quantity of the proteins of this invention to effectively treat the patient.
  • Amoung various uses of the recombinant fusion proteins of the present invention are included a variety of disease conditions caused by specific human cells that may be elimated by the toxic action of the protein.
  • One preferred application is the treatment of autoimmune conditions such as graft-verus-host disease, organ transplant rejection, type I diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis and the like caused by T and B cells.
  • the example disclosed herein is illustrative.
  • Another preferred application is for the treatment of cancer, caused by malignant cells of various types.
  • the fusion proteins may also be used in vitro , for example in the elimination of harmful cells from bone marrow before transplant.
  • the antibody portion of the fusion protein is chosen accordingly to the intended use.
  • Proteins on the membranes of T cells that may serve as targets for the antibody include CD2 (T11), CD3, CD4 and CD8.
  • Proteins found predominantly on B cells that might serve as targets include CD10 (CALLA antigen), CD19 and CD20.
  • CD45 is a possible target that occurs broadly on lymphoid cells. These and other possible target lymphocyte antigens for the antibody are described in Leucocyte Typing III, A.J. McMicheal, ed., Oxford University Press, 1987.
  • Antigens found on cancer cells that may serve as targets for the antibody include carcinoembryonic antigen (CEA), the transferrin receptor, P-glycoprotein, c-erbB2, and antigens described in the Abstracts of the Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer (San Diego, CA 1988).
  • CEA carcinoembryonic antigen
  • P-glycoprotein P-glycoprotein
  • c-erbB2 transferrin receptor
  • Those skilled in the art will realize that antibodies may be chosen that bind to antigens expressed on still other types of cells, for example membrane glycoproteins or growth factor or hormone receptors such as epidermal.growth factor receptor and the like.
  • a plasmid designated herein as pVC70108 was assembled such that it contained an ATG encoding an initiating methionine, a 348 bp DNA segment encoding anti-Tac V H jointed to a 318 bp DNA segment encoding V L through a 45 bg linker; V L was in turn joined to a DNA segment encoding amino acids 253-613 of PE ( Figure 1).
  • the complete sequences of the V H -V L -linker-PE40 DNA segment and of the encoded anti-Tac (Fv)-PE40 fusion protein are presented in Table 1.
  • PCR polymerase chain reaction
  • Plasmids carrying full length cDNAs, encoding heavy and light chains of antiTac, as EcoRI inserts in pUC18 were used as template. After PCR amplification, two fragments: (1) 413 bp fragment containing variable domain of the heavy chain, and amino terminal part of the peptide linker; (2) a 396 bp fragment containing carboxy terminal part of the peptide linker and variable domain of light chain, were isolated. 413 bp fragment was cut with NdeI and KpnI to yield a 377 by fragment. 396 bp fragment was restricted with KpnI and HindIII to produce a 340 bp fragment.
  • plasmid pVc20 carrying gene encoding a PE derivative PE43 (Chaudhary et al, Proc. Natl. Acac. Sci. USA , 85:2939-2943, 1988), was restricted with NdeI and HindIII and dephosphorylated to isolate a 3.75 Kb fragment. This was then ligated with 377 bp and 340 bp fragments isolated earlier.
  • the resultant plasmid pVC701 contains a fusion gene under T7 promoter. This gene contains four extra bases in the peptide linker.
  • Plasmid pVC701 was cut with KpnI, treated with T4 DNA polymerase to remove 3' overhangs and ligated to isolated plasmid pVC701020.
  • pVC701020 (4.4 Kb) encodes a fusion protein comprised of variable domains of antiTac and PE43.
  • pVC701020 was restricted with HindIII, treated with SI nuclease to remove 5' overhangs, cut with BamHI and dephosphorylated to isolate a 3.65 kb fragment. Separately, pVC701020 was cut with AvaI, treated with SI nuclease and cut with BamHI to isolate a 750 bp fragment. 3.65 Kb and 750 bp fragments were ligated together to generate a plasmid pVC70108.
  • pVC70108 carries a fusion gene encoding V H linked to V L through a 15 amino acid linker, and V L linked to amino acids 253 to 613 of PE. A methionine codon has been created at the 5' end of V H .
  • the assembled gene is under the control of a T7 promoter.
  • the authenticity of the coding region of the plasmid was confirmed by DNA sequencing (data not shown).
  • a deposit of plasmid pVC70108 has been made at the ATCC, Rockville, Maryland on March 31, 1989 under the accession number 67913.
  • the deposit shall be viably maintained, replacing if it becomes non-viable, for a period of 30 years from the date of the deposit, or for 5 years from the last date of request for a sample of the deposit, whichever is longer, and made available to the public upon issuance of a patent from this application, without restriction, in accordance with the provisions of the law.
  • the Commissioner of Patents and Trademarks, upon request, shall have access to the deposit.
  • E. coli strain BL21 ( ⁇ DE3) carrying plasmid p70108 produced large amounts of a protein of approximately 65 kDa, as shown by SDS PAGE (lane 1, Fig. 2b).
  • the 65 kDa chimeric protein reacted with an antibody to PE (data not shown).
  • the fusion protein was mostly contained in the 100,000 xg pellet (lane 3, Fig. 2b) of the sonicated spheroplasts (lane 2, Fig. 2b). This pellet was used as the source to prepare anti-Tac(Fv)-PE40.
  • HUT-102 cells were washed twice with serum free medium and plated in RPMI 1640 medium with 5% fetal bovine serum at 3 X 105 cells/well in 24-well plates.
  • Various dilutions of anti-Tac(Fv)-PE40 were prepared in PBS with 0.2% human serum albumin and added to appropriate wells. After 20 hours the cells were labeled with 3H-leucine for 90 min and the radioactivity in the TCA precipitate of the cell pellet determined. The results are expressed as % of control with no toxin added. For competition, 10 ⁇ g of anti-Tac(Fv)-PE40.
  • I-125 labeled anti-Tac (2 ⁇ Ci/ ⁇ g) as tracer was used at 1.5 ng per assay with varying concentrations of competitor and 4 X 105 HUT-102 cells as source of Tac antigen in 0.2 ml of binding buffer (RPMI 1640 with 10% fetal bovine serum, 100 ⁇ g/ml human IgG, 0.1% sodium azide), and incubated at room temperature (22°-24°C) with mixing for 2 hours. Under these conditions, the concentration of tracer is 50 pM and Tac peptide 500 pM.
  • the anti-Tac antibody binds to the p55 subunit (Tac antigen) of the IL-2 receptor, which is present in large amounts on HUT-102 cells (Uchiyama et al, 1981, J. Immunol. 126, 1393-1397), the chimeric protein was initially tested for cytotoxicity on HUT-102 cells, as described above.
  • Anti-Tac(Fv)-PE40 inhibited protein synthesis in a dose-dependent manner with an ID50 of 0.15 ng/ml (2.3 X 10 ⁇ 1M) in a 20 hour assay (Fig. 3 and Table 2). At concentrations of more than 4 ng/ml, there was complete inhibition of protein synthesis.
  • Several specificity controls were carried out.
  • Anti-Tac-PE anti-Tac-PE
  • Pe40 killed HUT102 cells Korean adiol-PE
  • Anti-TacPE has an ID50 of about 1.2 ng/ml
  • anti-Tac-PE40 similarly prepared had an ID of 13 ng/ml.
  • anti-Tac(Fv)-PE40 (65 kDa) is about 30% of the molecular weight of anti-Tac-PE (216 kDa)
  • the chimeric toxin of the present invention is on a molar basis several-fold more active than anti-Tac-PE and considerably more active than anti-Tac-PE40.
  • the very high activity of anti-Tac(Fv)-PE40 on the target HUT102 cells about 10-fold higher than the chemically prepared anti-Tac-PE40 or the recombinant fusion protein IL-2-PE40 (Lorberboum-Galski et al., 1988, Proc. Nat. Acd. Sci.
  • ID50 is the concentration of toxin that inhibits protein synthesis by 50% as compared to a control with no toxin added. All the essays were done in duplicate and repeated three times.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (14)

  1. Structure comprenant des segments de DNA dirigeant la synthèse d'une protéine recombinante de fusion dans un vecteur d'expression approprié, dans laquelle ladite protéine de fusion et de l'anti-Tac(Fv)-PE40.
  2. Structure selon la revendication 1, dans laquelle les-segments de DNA sont contenus dans un plasmide.
  3. Structure selon la revendication 2, comprenant du plasmide de ATCC no. 67913.
  4. Cellule procaryote ou eucaryote transformée ou transfectée par la structure selon la revendication 1.
  5. Protéine recombinante de fusion anticorps-PE40 possédant au moins l'activité de translocation et de ribosylation de l'ADP du PE, dans laquelle ladite protéine de fusion est de l'anti-Tac(Fv)-PE40.
  6. Protéine de fusion selon la revendication 5, dans laquelle ladite protéine a une chaîne polypeptidique simple.
  7. Composition comprenant une quantité efficace de la protéine de fusion selon la revendication 5 pour détruire des cellules portant un récepteur ou un antigène auquel se lie l'anticorps, et un porteur acceptable du point de vue pharmaceutique.
  8. Procédé de réalisation d'une cytotoxicité ciblée, comprenant l'établissement d'un contact avec des cellules ciblées comme devant être détruites avec une quantité cytotoxique de la composition selon la revendication 7, lesdites cellules ciblées étant celles comportant des récepteurs ou des antigènes auxquels se lie l'anticorps, la composition ne présentant toutefois pas de cytotoxicité notable pour les cellules ne possédant pas de récepteurs ou d'antigènes pour la liaison dudit anticorps.
  9. Structure selon la revendication 1, dans laquelle ladite protéine de fusion est un polypeptide à chaîne simple.
  10. Cellule selon la revendication 4, transfectée ou transformée par la structure selon la revendication 9.
  11. Procédé de production d'une protéine recombinante de fusion anticorps PE40, comprenant les étapes de culture de la cellule selon la revendication 4 et de récupération de la protéine recombinante de fusion anticorps PE40 de la culture.
  12. Procédé de production d'une protéine recombinante de fusion anticorps PE40, comprenant les étapes de culture de la cellule selon la revendication 9 et de récupération de la protéine recombinante de fusion anticorps PE40 de la culture.
  13. Structure selon la revendication 1, dans laquelle ladite protéine de fusion est plus active qu'une protéine non recombinante de fusion identique.
  14. Structure selon la revendication 1, dans laquelle les séquences de codage pour la région variable de la chaîne lourde sont suivies par des séquences de codage pour le domaine variable de la chaîne légère, suivies par le gène PE40.
EP90907767A 1989-04-21 1990-04-20 Proteine recombinante de fusion anticorps-toxine Expired - Lifetime EP0469065B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34136189A 1989-04-21 1989-04-21
US341361 1989-04-21
PCT/US1990/002097 WO1990012592A1 (fr) 1989-04-21 1990-04-20 Proteine recombinante de fusion anticorps-toxine

Publications (3)

Publication Number Publication Date
EP0469065A1 EP0469065A1 (fr) 1992-02-05
EP0469065A4 EP0469065A4 (en) 1992-07-08
EP0469065B1 true EP0469065B1 (fr) 1996-05-29

Family

ID=23337235

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90907767A Expired - Lifetime EP0469065B1 (fr) 1989-04-21 1990-04-20 Proteine recombinante de fusion anticorps-toxine

Country Status (10)

Country Link
EP (1) EP0469065B1 (fr)
JP (1) JPH0829101B2 (fr)
AT (1) ATE138688T1 (fr)
AU (1) AU641392B2 (fr)
CA (1) CA2053911C (fr)
DE (1) DE69027210T2 (fr)
DK (1) DK0469065T3 (fr)
ES (1) ES2091824T3 (fr)
IL (1) IL94159A0 (fr)
WO (1) WO1990012592A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2085329T3 (es) * 1989-02-17 1996-06-01 Merck & Co Inc Agente anticanceroso proteico.
AU631200B2 (en) * 1989-02-17 1992-11-19 Merck & Co., Inc. Production of modified pe40
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
DE69230798T2 (de) * 1991-09-30 2000-08-03 Us Health Rekombinante immuntoxine
JP3024311B2 (ja) 1991-10-03 2000-03-21 味の素株式会社 Ｉｌ−２受容体重鎖に結合するポリペプチド
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
EP0625200B1 (fr) * 1992-02-06 2005-05-11 Chiron Corporation Proteine de liaison biosynthetique pour marqueur de cancer
IL123294A0 (en) * 1995-10-19 1998-09-24 Bristol Myers Squibb Co Monoclonal antibody BR110 and uses thereof
IL116559A (en) * 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
AU738749B2 (en) * 1996-10-23 2001-09-27 Wake Forest University Targeted cytotoxic cells
SI2170956T1 (sl) 2007-06-15 2015-02-27 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Zdravljenje tumorjev z uporabo specifičnega protitelesa proti L1
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
BR112017006626A2 (pt) 2014-09-30 2018-07-03 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts novas moléculas de ligação que se ligam a l1
WO2016146833A1 (fr) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarqueurs de résistance à la nad(+)-diphtamide adp-ribosyltransférase
EP3184547A1 (fr) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anticorps anti-tpbg et procédés d'utilisation
CA3045857A1 (fr) 2016-12-22 2018-06-28 Universita Degli Studi Magna Graecia Catanzaro Anticorps monoclonal ciblant un epitope de cd43 unique associe au cancer sialoglycosile

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE25197T1 (de) * 1982-05-12 1987-02-15 Harvard College Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4867962A (en) * 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
ES2085329T3 (es) * 1989-02-17 1996-06-01 Merck & Co Inc Agente anticanceroso proteico.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 86, no. 6, 1988; V.E. KELLEY et al., AN 58970 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, 05 July 1988, Baltimore, MD (US); T. KONDO et al., pp. 9470-9475 *

Also Published As

Publication number Publication date
IL94159A0 (en) 1991-01-31
AU5562790A (en) 1990-11-16
ATE138688T1 (de) 1996-06-15
DE69027210D1 (de) 1996-07-04
DK0469065T3 (da) 1996-07-15
AU641392B2 (en) 1993-09-23
DE69027210T2 (de) 1997-01-23
ES2091824T3 (es) 1996-11-16
WO1990012592A1 (fr) 1990-11-01
EP0469065A4 (en) 1992-07-08
CA2053911A1 (fr) 1990-10-22
JPH0829101B2 (ja) 1996-03-27
EP0469065A1 (fr) 1992-02-05
JPH04504363A (ja) 1992-08-06
CA2053911C (fr) 1999-11-02

Similar Documents

Publication Publication Date Title
US6051405A (en) Constructs encoding recombinant antibody-toxin fusion proteins
US5696237A (en) Recombinant antibody-toxin fusion protein
EP0469065B1 (fr) Proteine recombinante de fusion anticorps-toxine
AU656352B2 (en) Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diphtheria toxin
US5821238A (en) Recombinant pseudomonas exotoxin with increased activity
US5932448A (en) Bispecific antibody heterodimers
Chaudhary et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
RU2126046C1 (ru) Рекомбинантное антитело, полинуклеотид (варианты), способ получения тяжелых и/или легких цепей рекомбинантного антитела (варианты)
US5889157A (en) Humanized B3 antibody fragments, fusion proteins, and uses thereof
EP0467536B1 (fr) Méthode de traitement des cellules cancéreuses de la vessie
WO1992015327A1 (fr) Immunotoxines bicatenaires de recombinaison
AU636453B2 (en) An improved toxin for construction of immunotoxins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19911014

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: QUEEN, CARY, L.

Inventor name: PASTAN, IRA, H.

Inventor name: FITZGERALD, DAVID

Inventor name: WALDMANN, THOMAS, A.

Inventor name: CHAUDHARY, VIJAY KUMAR

A4 Supplementary search report drawn up and despatched

Effective date: 19920518

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE

Owner name: PROTEIN DESIGN LABS, INC.

17Q First examination report despatched

Effective date: 19940331

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 138688

Country of ref document: AT

Date of ref document: 19960615

Kind code of ref document: T

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

REF Corresponds to:

Ref document number: 69027210

Country of ref document: DE

Date of ref document: 19960704

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2091824

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20090427

Year of fee payment: 20

Ref country code: DK

Payment date: 20090428

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20090505

Year of fee payment: 20

Ref country code: DE

Payment date: 20090429

Year of fee payment: 20

Ref country code: SE

Payment date: 20090429

Year of fee payment: 20

Ref country code: AT

Payment date: 20090401

Year of fee payment: 20

Ref country code: IT

Payment date: 20090428

Year of fee payment: 20

Ref country code: FR

Payment date: 20090417

Year of fee payment: 20

Ref country code: NL

Payment date: 20090423

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20090528

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20090427

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090429

Year of fee payment: 20

REG Reference to a national code

Ref country code: NL

Ref legal event code: V4

Effective date: 20100420

BE20 Be: patent expired

Owner name: *PROTEIN DESIGN LABS INC.

Effective date: 20100420

Owner name: THE *UNITED STATES OF AMERICA AS REPRESENTED BY TH

Effective date: 20100420

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20100419

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20100421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100420

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100419

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20100420